As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.
13 Analysts have issued a Clene Inc forecast:
13 Analysts have issued a Clene Inc forecast:
Jun '25 |
+/-
%
|
||
Revenue | 0.29 0.29 |
34%
34%
|
|
Gross Profit | 0.23 0.23 |
36%
36%
|
|
EBITDA | -25 -25 |
27%
27%
|
EBIT (Operating Income) EBIT | -27 -27 |
26%
26%
|
Net Profit | -30 -30 |
2%
2%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of therapeutics for neurodegenerative diseases. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded on August 12, 2020 and is headquartered in Salt Lake City, UT.
Head office | United States |
CEO | Robert Etherington |
Employees | 76 |
Founded | 2013 |
Website | clene.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.